Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
We break down the top-performing altcoins over the past five years, spotlighting winners and the factors driving their returns for smarter investing.
25,048 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Unity Software’s latest guidance sparked a sharp rally, underscoring how Vector AI could redefine monetization in int...
Finance of America reported a profitable first quarter, reversing Q4 losses as originations climbed and portfolio gai...
Joby Aviation stock today? Investors are asking why the shares moved. This article breaks down the catalysts, what’s ...
AI demand is broadening from chipmakers to the hardware backbone that powers deployments, a shift that could lift inf...
Bitcoin is testing a crucial resistance zone after a strong monthly rally. Analysts say the bitcoin (btc) bottom isn’...
This article dives into EverCommerce (evcm) 2026 earnings, unpacking Q1 results, growth drivers, and the implications...
As Republic Services reveals Q1 2026 figures, investors gain a window into revenue growth, margins, and cash flow. Th...
Wheaton's Q1 2026 earnings transcript offers clues about margins, cash flow, and future growth in the gold streaming ...
Tariffs launched during the Trump era reshaped some prices and supply chains, but their overall effect on the trade b...
The latest CBO budget update shows the Treasury's interest costs rising to nearly $3 billion per day as debt nears $3...
Massive accumulation by large holders and dwindling exchange reserves are fueling debate over a possible Bitcoin bott...